

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Care of Patients with Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following Grade ≥ 3 adverse events was most commonly reported in patients receiving pirtobrutinib for previously treated chronic lymphocytic leukemia (CLL) in the Phase III BRUIN CLL-321 trial?
 - a. Atrial fibrillation
 - b. Keratitis
 - c. Hemorrhage
 - d. Infections
2. What was the approximate incidence of Grade ≥ 3 CRS (cytokine release syndrome) among patients receiving lisocabtagene maraleucel for relapsed/refractory (R/R) CLL in the Phase I/II TRANSCEND CLL 004 trial?
 - a. Lower than 1%
 - b. Lower than 5%
 - c. Lower than 10%
 - d. Higher than 10%
3. Which of the following results best describes response rates with lisocabtagene maraleucel and ibrutinib for patients with R/R CLL in the Phase I/II TRANSCEND CLL 004 trial?
 - a. Overall response rate (ORR) ~40% and complete response rate (CRR) ~15%
 - b. ORR ~60% and CRR ~30%
 - c. ORR >80% and CRR ~45%
4. Which of the following statements best describes progression-free survival outcomes with pirtobrutinib compared to idelalisib/rituximab or bendamustine/rituximab for Bruton tyrosine kinase (BTK) inhibitor-pretreated CLL in the Phase III BRUIN CLL-321 trial?
 - a. Outcomes were similar in both arms of the study
 - b. Pirtobrutinib was superior to idelalisib/rituximab but not to bendamustine/rituximab
 - c. Pirtobrutinib was superior to investigator's choice of idelalisib/rituximab or bendamustine/rituximab
5. Pirtobrutinib targets which of the following BTK mutations that is associated with resistance to covalent BTK inhibitors?
 - a. T474I
 - b. C481S
 - c. L528W